Miguel Franco
Pulmonary Disease · Houston, TXNPI 1740263565
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,105 and has fallen 69.2% since, to $341 in 2022. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 105 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$306
- Novo Nordisk$260
- Regeneron Healthcare Solutions, Inc.$195
- AstraZeneca$174
- Boehringer Ingelheim$151
- Johnson & Johnson$137
- plus $604 from 13 others
Across 74 payments — averaging $4173.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$198K
- AstraZeneca$74K
- Ferring International Pharmascience Center US$13K
- Ferring Pharmaceuticals AS$11K
- Astrazeneca UK Limited$8K
- Shionogi Inc$5K
What the payments were for
- Food & beverage$1,826100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $306 |
| Novo Nordisk | 13 | $260 |
| Regeneron Healthcare Solutions, Inc. | 7 | $195 |
| AstraZeneca | 12 | $174 |
| Boehringer Ingelheim | 8 | $151 |
| Johnson & Johnson | 8 | $137 |
| Bayer | 8 | $122 |
| Amarin Pharma, Inc. | 5 | $95 |
| AbbVie | 5 | $88 |
| Sanofi-aventis U.S. LLC | 4 | $52 |
| Lilly USA, LLC | 3 | $40 |
| Mylan Specialty L.p. | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Mannkind Corporation | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Amgen(2 entities) | 2 | $24 |
| Novartis | 1 | $22 |
| Genentech USA, Inc. | 1 | $18 |
| United Therapeutics Corporation | 1 | $15 |
How this compares
$1,826 in reported general payments places this provider in the 45th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Nicola HananiaHouston$1.3M
- Sandeep SahayHouston$378K
- Zeenat SafdarHouston$291K
- Howard HuangHouston$194K
- Brandy McKelvyHouston$168K
- Alexander StadnykHouston$158K
- Lisa KopasHouston$120K
- Sandeep GuptaHouston$118K
- Roberto CasalHouston$113K
- Dileep PuppalaHouston$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.